Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects

Archives of Internal Medicine

Volumn 160, Issue 1, 2000, Pages 49-52

  Bloemenkamp, Kitty W M ^a   Rosendaal, Frits R ^a   Helmerhorst, Frans M ^a   Vandenbroucke, Jan P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; ESTRADIOL; ETHINYLESTRADIOL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; CASE CONTROL STUDY; CONTRACEPTION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PREMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS;

EID: 0034627887     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.1.49     Document Type: Article

References (30)

1. Venous thromboembolic disease and combined oral contraceptives: results of international multi centre case-control study: World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1575-1582
2. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third-generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ. 1996;312:83-88.
3. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestogen. Lancet. 1995;346:1593-1596.
4. Poulter NR, Farley TMM, Chang CL. Marmot MG, Meirik O. Safety of combined oral contraceptive pills [authors' reply]. Lancet. 1996;347:547.
5. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. BMJ. 1968;2:199-205.
6. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. BMJ. 1969;2:651-657.
7. Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol. 1969; 90:365-380.
8. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-1457.
9. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication: the GTH Study Group on Natural Inhibitors, Thromb Haemost. 1994;71: 548-552.
10. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-1506.
11. Koster T, Rosendaal FR, Brit E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85:2756-2761.
12. Bertina RM, Koeleman RPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
13. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden. Blood. 1995;85:1504-1508.
14. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
15. Hannaford P. Cardiovascular Disease and Steroid Hormone Contraception: Report of a WHO Scientific Group. Geneva, Switzerland: World Health Organization; 1998. WHO Technical Report Series, No. 877.
16. Bloemenkamp KWM, Rosendaal FR, Büller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med. 1999;159:65-70.
17. Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. Contraception. 1998;57:169-181.
18. Shapiro S. Oral contraceptives and venous thromboembolic disease, surgically confirmed gall-bladder disease, and breast tumours: report from the Boston Collaborative Drug Surveillance Programme. Lancet. 1973;1:1399-1404.
19. Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol. 1987;69:91-95.
20. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception. 1997;56:141-146.
21. Farley TM, Meirik O, Marmot MG, Chang CL, Poulter NR. Oral contraceptives and risk of venous thromboembolism: impact of duration of use. Contraception. 1998; 57:61-65.
22. WHO Collaborative Study. Cardiovascular disease and the use of oral contraceptives. Bull World Health Organ. 1989;67:417-423.
23. Oral contraceptives, venous thrombosis and varicose veins: Royal College of General Practitioners' Oral Contraception Study. J R Coll Gen Pract. 1978;28: 393-399.
24. Henkens CMA, Bom VJJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C: influence of oral contraceptives and sex. Thromb Haemost. 1995;73: 402-404.
25. Østerud B, Robertsen R, Svang GB, Thijssen F. Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coagul Fibrinolysis. 1994; 5:853-854.
26. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol. 1995;91:465-470.
27. Bokarewa MI, Falk G, Sten-Linder M, Egberg N, Blomback M, Bremme K. Thrombotic risk factors and oral contraception. J Lab Clin Med. 1995;126:294-298.
28. Rosing J, Tans G, Nicolaes GAF, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997;97:233-238.
29. Briët E, van der Meer FJ, Rosendaal FR, Houwing-Duistermaat JJ, van Houwelingen HC. The family history and inherited thrombophilia. Br J Haematol. 1994; 87:348-352.
30. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ. 1996;313:1127-1130.